Exelixis Inc (EXEL) Financials
Key financial figures for Exelixis Inc (Q3 2026).
Exelixis Q3 2026: total revenues $658.7M (+10% YoY), cabozantinib franchise U.S. net product revenues $604.9M (+11%), GAAP diluted EPS $0.85, non-GAAP $0.94; FY2026 revenue guidance unchanged. Total revenues were $658.7M versus $597.8M a year earlier (about +10%, calculated). Net product revenues, all from the cabozantinib franchise in the U.S., were $604.9M versus $542.9M, which the release attributes to higher sales volume and a higher average net selling price. CABOMETYX U.S. net product revenues were $603.2M and COMETRIQ $1.8M. Royalties on ex-U.S. cabozantinib sales by Ipsen and Takeda were $51.8M. Collaboration revenues were $53.8M versus $54.8M, on lower milestone-related revenue and lower development cost reimbursements. Income from operations was $268.4M versus $236.5M. On the outlook: FY2026 (updated October 29, 2026): total revenues $2.500B to $2.550B and net product revenues $2.300B to $2.350B, both unchanged from August 5; R&D $825M to $875M and SG&A $575M to $625M, unchanged; cost of goods sold about 4% of net product revenues (was 3.5% to 4.5%); effective tax rate 16% to 18% (was 21% to 23%). Revenue guidance does not reflect any U.S. zanzalintinib approval or launch. Figures are for Q3 2026, as Exelixis, Inc. reported them.
- Revenue
- $659M
- Net Income
- $218M
- EPS
- $0.88
- Total Assets
- $2.5B
- Operating Cash Flow
- $280M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $659M | $218M | $0.85 | 40.75% | $277M |
| Q2 FY2026 | $629M | $212M | $0.82 | 39.51% | $298M |
| Q1 FY2026 | $611M | $210M | $0.79 | 41.15% | $250M |
| Q4 FY2025 | $599M | $245M | $0.88 | 39.29% | $326M |
| Q3 FY2025 | $598M | $194M | $0.69 | 39.57% | $284M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $2.3B | $783M | $2.78 | 37.59% | $844M |
| FY2024 | $2.2B | $521M | $1.76 | 27.88% | $634M |
| FY2023 | $1.8B | $208M | $0.65 | 9.34% | $170M |
Frequently asked questions
What was Exelixis, Inc.'s revenue last quarter?
Exelixis, Inc. reported revenue of $658.7 million for Q3 FY2026, up 10.2% from the same period a year earlier.
Is Exelixis, Inc. profitable?
Yes. Exelixis, Inc. reported net income of $218.1 million for Q3 FY2026, a net margin of 33.11% on revenue.
How has Exelixis, Inc.'s margin trended?
Operating margin was 40.75% in Q3 FY2026, compared with 39.57% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Exelixis, Inc. generate?
Exelixis, Inc. generated free cash flow of $277.5 million in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Exelixis Inc on SentiSense, with up to forty quarters and twenty fiscal years of history.